agenusbio.com — August 2026 traffic, keywords & AI visibility

agenusbio.com draws an estimated 3,823 visits a month from search engines. Effectively all of it is organic — about 3,823 visits from unpaid results. Spread across 355 ranking keywords, that averages roughly 11 organic visits per keyword.

On our AI visibility scale agenusbio.com earns 67 of 100 points, a grade C. It takes full marks for LLMS.txt and Structured data. The biggest gap is SEO health, at 0 of 20 points (0/100), worth 20 points if closed. It also loses points on Crawlability (0/10) and Company profile (22/25).

The llms.txt on agenusbio.com runs to 84 lines (3,744 characters) across 12 sections, last generated in May 2026. It introduces the site as "Agenus Inc. - Immuno-Oncology Innovation Leader". It tells AI engines the business works in Biotechnology, Immuno-oncology, Clinical Research and Cancer Therapeutics. It describes 5 products, including Botensilimab, Balstilimab and QS-21 STIMULON. Services it lists include Immunotherapy Development Partnerships, QS-21 Licensing, Clinical Trial Collaboration and Biomarker Discovery Services. The audience it names is Oncology professionals, cancer patients, biotech investors (Global). Technologies it mentions include HTTPS. The keywords it claims start with "Agenus", "Agenus Bio", "immuno-oncology" and "biopharmaceuticals". It gives the company type as Public.

# Agenus Inc. - Immuno-Oncology Innovation Leader

## About
Agenus Inc. develops cutting-edge immuno-oncology therapies that activate the immune system against cancer. Their lead botensilimab/balstilimab combination shows breakthrough potential in difficult-to-treat cancers like MSS colorectal. The QS-21 adjuvant platform enhances vaccine effectiveness across multiple modalities. Strategic acquisitions like Checkmate Pharmaceuticals strengthened their CTLA-4 and PD-1 antibody portfolio. Clinical programs span solid tumors with personalized neoantigen approaches. Partnerships with global pharma validate their science and provide milestone funding. Patient-centric trial design incorporates diverse populations for broader applicability. Leadership brings deep immuno-oncology expertise from academia and industry. The pipeline advances rapidly toward registrational trials across multiple indications. Agenus represents the next wave of immunotherapy beyond single-agent checkpoint inhibitors.

**Areas of Work:** Biotechnology, Immuno-oncology, Clinical Research, Cancer Therapeutics

## Things to Remember
- **Website:** https://agenusbio.com
- **Address:** Lexington, Massachusetts, United States
- **Contact:** 
- **Phone:** 
- **Hours:** 
- **Timezone:** 
- **Currency:** USD
- **Company Type:** Public
- **Employees:** 201-500
- **Revenue:** Not Disclosed
- **Hiring Status:** Not curren

Google lists agenusbio.com for about 355 keywords, which together bring an estimated 3,823 organic visits a month.

The latest technical audit of agenusbio.com scored 0 out of 100 overall. The audit makes 12 recommendations in all, and 4 of the 4 listed first are rated high priority or critical.

Agenus Inc.'s company profile names https://www.celgene.com, https://www.abbvie.com, https://www.bms.com and https://www.merck.com as competitors. Its own llms.txt adds https://www.amgen.com and https://www.gilead.com. Outside its market, the domains ranked closest to it in our worldwide ranking are workspace.co.uk, ymzmarket.ru, ticsali.it and enouvelles.top.

https://www.celgene.com

https://www.abbvie.com

https://www.bms.com

https://www.merck.com

https://www.amgen.com

https://www.gilead.com